New User:
-or-
Username:
Password:
Forgot your password?
News Breaks
March 17, 2010
16:37 EDTMNOV
theflyonthewall.com: MedicNova reports positive results from Phase 2 trial of MN-221
MediciNova reported positive preliminary results from a Phase Ib clinical trial to evaluate the safety and efficacy of MN-221 in patients with stable, moderate to severe chronic obstructive pulmonary disease. There were no clinically significant safety concerns noted. Preliminary results demonstrated clinically significant improvements in percent change in forced expiratory volume in one second. :theflyonthewall.com



News For MNOV From The Last 14 Days
Check below for free stories on MNOV the last two weeks.
There are 4 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing.
February 3, 2012
12:00 EDTMNOV
theflyonthewall.com: MedicNova falls 14.6%

Subscribe for More Information :theflyonthewall.com

February 2, 2012
12:00 EDTMNOV
theflyonthewall.com: MedicNova rises 33.3%

Subscribe for More Information :theflyonthewall.com
10:00 EDTMNOV
theflyonthewall.com: MedicNova rises 29.6%
MedicNova is up 29.6%, or 56c, to $2.45 :theflyonthewall.com

February 1, 2012
06:31 EDTMNOV
theflyonthewall.com: MedicNova receives notice of patent allowance for a method of treating MS
MediciNova Inc, a biopharmaceutical company traded on the NASDAQ Global Market and the Jasdaq Market of the Osaka Securities Exchange (4875), announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application, which covers the use of ibudilast for the treatment of progressive forms of multiple sclerosis. Ibudilast (MN-166), is the company's lead drug development candidate for certain neurological conditions, including progressive multiple sclerosis, neuropathic pain, and drug addiction. :theflyonthewall.com